Liquidia (LQDA) Liabilities and Shareholders Equity (2019 - 2026)
Liquidia (LQDA) posted quarterly Liabilities and Shareholders Equity of $401.5 million for Q1 2026, up 76.55% year-over-year from $227.4 million in Q1 2025, and up 22.44% quarter-over-quarter from $327.9 million in Q4 2025.
Liquidia (LQDA) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Liquidia's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $401.5 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 76.55% year-over-year to $401.5 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 42.22% YoY), while the FY2025 annual figure was $327.9 million, up 42.39% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $401.5 million, up from $327.9 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $401.5 million in Q1 2026, with the low at $93.5 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $177.4 million (2024), against an average of $195.5 million.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity dropped 15.79% in 2023, then surged 126.52% in 2024.
- Liquidia's Liabilities and Shareholders Equity stood at $129.2 million in 2022, then dropped by 8.41% to $118.3 million in 2023, then jumped by 94.63% to $230.3 million in 2024, then surged by 42.39% to $327.9 million in 2025, then grew by 22.44% to $401.5 million in 2026.
- Business Quant data shows LQDA's Liabilities and Shareholders Equity at $401.5 million in Q1 2026, $327.9 million in Q4 2025, and $276.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Liquidia | 6.39 Bn | 6.11 Bn | 160.92 Mn | 521.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 521.92 Mn |
| Mar 31, 2026 | 401.53 Mn |
| Dec 31, 2025 | 327.93 Mn |
| Sep 30, 2025 | 275.98 Mn |
| Jun 30, 2025 | 257.41 Mn |
| Mar 31, 2025 | 227.43 Mn |
| Dec 31, 2024 | 230.31 Mn |
| Sep 30, 2024 | 252.89 Mn |
| Jun 30, 2024 | 177.36 Mn |
| Mar 31, 2024 | 197.12 Mn |
| Dec 31, 2023 | 118.33 Mn |
| Sep 30, 2023 | 111.64 Mn |
| Jun 30, 2023 | 121.60 Mn |
| Mar 31, 2023 | 128.92 Mn |
| Dec 31, 2022 | 129.20 Mn |
| Sep 30, 2022 | 132.57 Mn |
| Jun 30, 2022 | 139.08 Mn |
| Mar 31, 2022 | 93.53 Mn |
| Dec 31, 2021 | 93.73 Mn |
| Sep 30, 2021 | 100.30 Mn |